Research
Hormonal
Genetic loss-of-function variants of the GIP receptor are associated with lower body mass index (BMI) and reduced obesity prevalence in humans.
People with certain genetic variations that reduce GIP receptor function tend to have lower body weight. This genetic insight supports the development of drugs that block GIP receptors to achieve similar weight loss benefits.
GoodSupportsHIGH confidence
Specifically, carriers of GIPR variants that are pharmacologically classified as loss-of-function variants with reduced cell surface expression, cAMP production, beta arrestin 2 recruitment, internalization, and endosomal signaling have consistently been associated with lower adiposity—including BMI (103) and nominally lower obesity-related traits, prevalence of obesity (39, 97–99).
Why this rating
Supported by GWAS and genetic studies, though some meta-analyses show no association with bone density, the BMI association is consistent.
Source
The evolution of the therapeutic concept ‘GIP receptor antagonism’
Frederikke Koefoed-Hansen et al. · Frontiers in Endocrinology · 2025
DOI 10.3389/fendo.2025.1570603
narrative_reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Endogenous GIP acts as an incretin that potentiates glucose-stimulated insulin secretion, and its inhibition via GIP receptor antagonists reveals this physiological role.Strong
- GIP receptor antagonism, when combined with GLP-1 receptor agonism, produces superior weight loss and glycemic control compared to GLP-1 receptor agonism alone.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →